{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:54:32Z","timestamp":1783457672493,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031272","name":"Eureka Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.omta.2026.201730","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:17:38Z","timestamp":1775182658000},"page":"201730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9151-6197","authenticated-orcid":false,"given":"Lupita S.","family":"Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyou","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-2112","authenticated-orcid":false,"given":"Saul J.","family":"Priceman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201730_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omta.2026.201730_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.omta.2026.201730_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.omto.2020.06.014","article-title":"PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model","volume":"18","author":"Alzubi","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omta.2026.201730_bib4","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/1535-7163.MCT-12-0042","article-title":"Regression of human prostate cancer xenografts in mice by AMG 212\/BAY2010112, a novel PSMA\/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens","volume":"11","author":"Friedrich","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omta.2026.201730_bib5","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"Priceman SJ.PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201730_bib6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201730_bib7","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","article-title":"The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer","volume":"27","author":"Deegen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omta.2026.201730_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211053898","article-title":"PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?","volume":"13","author":"Giraudet","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.omta.2026.201730_bib9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues","volume":"30","author":"Kinoshita","year":"2006","journal-title":"World J. Surg."},{"key":"10.1016\/j.omta.2026.201730_bib10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.oooo.2018.01.011","article-title":"Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET\/CT","volume":"125","author":"Klein Nulent","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.omta.2026.201730_bib11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/s41598-021-04613-w","article-title":"Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging","volume":"12","author":"Kunikowska","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201730_bib12","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.117.204677","article-title":"68-Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging","volume":"59","author":"Rischpler","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.omta.2026.201730_bib13","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omta.2026.201730_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2019.37.7_suppl.301","article-title":"Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC)","volume":"37","author":"Bailis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201730_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw7888","article-title":"A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies","volume":"12","author":"Skokos","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201730_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030549","article-title":"Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives","volume":"13","author":"Heitmann","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omta.2026.201730_bib17","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.annonc.2020.08.869","article-title":"609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE\u00ae) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"31","author":"Tran","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omta.2026.201730_bib18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a Bite\u00ae Immune Therapy for Castration-Resistant Prostate Cancer: Phase I, Dose-Escalation Study Findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.omta.2026.201730_bib19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clgc.2023.12.008","article-title":"Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer","volume":"22","author":"Emperumal","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.omta.2026.201730_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2004.12.003","article-title":"Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3","volume":"435","author":"Laidler","year":"2005","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.omta.2026.201730_bib21","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","article-title":"IFN\u03b3 Is Critical for CAR T Cell\u2013Mediated Myeloid Activation and Induction of Endogenous Immunity","volume":"11","author":"Alizadeh","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omta.2026.201730_bib22","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201730_bib23","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1038\/s41467-023-40115-1","article-title":"Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting","volume":"14","author":"Lee","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201730_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omta.2026.201730_bib25","article-title":"Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201730_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omta.2026.201730_bib27","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201730_bib28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1023\/A:1027396714623","article-title":"Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72","volume":"17","author":"Blanco","year":"1997","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.omta.2026.201730_bib29","first-page":"1807","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.omta.2026.201730_bib30","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cncr.24795","article-title":"Anti\u2013prostate-Specific membrane antigen-based radioimmunotherapy for prostate cancer","volume":"116","author":"Tagawa","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.omta.2026.201730_bib31","first-page":"5237","article-title":"In Vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-specific Membrane Antigen1","volume":"60","author":"Smith-Jones","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.omta.2026.201730_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pros.10117","article-title":"Anti-tumor effects of toxins targeted to the prostate specific membrane antigen","volume":"53","author":"Fracasso","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.omta.2026.201730_bib33","first-page":"6095","article-title":"An \u03b1-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer1","volume":"60","author":"McDevitt","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.omta.2026.201730_bib34","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.ejca.2013.01.024","article-title":"A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer","volume":"49","author":"Frigerio","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omta.2026.201730_bib35","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201730_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2023.41.6_suppl.154","article-title":"Preliminary results from a phase 1\/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Stein","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201730_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1380764","article-title":"Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer","volume":"7","author":"Priceman","year":"2018","journal-title":"OncoImmunology"}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:42:03Z","timestamp":1782780123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3117387X26000650"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201730","relation":{"has-preprint":[{"id-type":"doi","id":"10.64898\/2026.03.05.709907","asserted-by":"object"}]},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-12-engineered human PSMA-CAR T cells for the treatment of advanced prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201730"}}